S-benzylglutathione

Summary

S‑benzylglutathione is a synthetic analogue of the tripeptide glutathione. In research it is employed as a structural probe and inhibitor of enzymes that use glutathione, such as glyoxalase I, glutathione S‑transferases (GSTs), and γ‑glutamyltransferase, and as a tool to study glutathione transport across cell membranes. It is not an approved drug and is used only in vitro or in animal experiments.

Mechanism of Action

Crystallographic studies show that S‑benzylglutathione binds the active‑site zinc ion of human glyoxalase I, mimicking a transition‑state enediolate and inducing a loop closure that blocks substrate access. In GST assays the compound acts as a product‑type inhibitor, competing with glutathione for the G‑site and reducing catalytic turnover of electrophilic substrates. It also interferes with low‑affinity glutathione transporters in rat liver sinusoidal vesicles, and can occupy the acceptor site of γ‑glutamyltransferase, slowing photo‑oxidative inactivation.

What the Research Shows

Structural work (1999) revealed S‑benzylglutathione coordinated the zinc ion in glyoxalase I, supporting an inner‑sphere catalytic mechanism. Enzyme kinetics (1985, 1983) demonstrated inhibition of rat liver GSTs, with potency comparable to other glutathione conjugates, and the first evidence of stereoselective product inhibition. A 1984 transport study showed that S‑benzylglutathione inhibited both high‑ and low‑affinity glutathione uptake in isolated hepatocyte membrane vesicles, especially the low‑affinity system. Photo‑oxidation experiments (1984) found the compound reduced irreversible loss of γ‑glutamyltransferase activity, indicating protective binding at the acceptor site. Collectively, these studies establish S‑benzylglutathione as a versatile biochemical probe for glutathione‑dependent processes.

Reported Benefits

Because it binds tightly to the zinc of glyoxalase I, S‑benzylglutathione serves as a reference inhibitor for mechanistic studies of the methylglyoxal detoxification pathway. Its ability to inhibit GSTs makes it useful for dissecting substrate specificity and for benchmarking inhibitor design. The transport inhibition data provide a tool for probing carrier‑mediated glutathione movement across hepatic membranes, and its protective effect on γ‑glutamyltransferase offers a means to explore enzyme stability under oxidative stress.

Limitations of the Evidence

All reported data are limited to purified enzymes, cell‑free systems, or rodent tissue preparations; no pharmacokinetic, toxicity, or efficacy information exists for whole‑organism or clinical contexts. Inhibition potency varies among GST isoforms and transport systems, and the compound’s effect on other glutathione‑dependent pathways has not been explored. Consequently, its relevance to human physiology remains uncertain, and it cannot be extrapolated to therapeutic use.

Safety Considerations

S‑benzylglutathione has only been evaluated in vitro and in short‑term animal studies. No adverse effects were reported in the cited experiments, but systematic safety assessments have not been performed. Potential toxicity, immunogenicity, or off‑target interactions in humans are unknown, so caution is advised when considering any translational application.

How It Is Administered

In research settings the compound is dissolved in aqueous buffers for addition to cell‑culture media or enzyme assays. In animal studies it has been administered by intraperitoneal injection. Formulations are simple solutions without specialized delivery systems, reflecting its status as a laboratory reagent rather than a therapeutic product.

Routes of Administration

Goals & Uses

• Antiparasitic leadInfectious Disease ResearchLow
• Anticancer activityOncologyLow
• GST characterizationBiochemical ToolModerate
• Glyoxalase I inhibitionEnzyme Inhibition / Biochemical ToolHigh

Contraindications

• Human therapeutic administrationClinical UseHigh

Adverse Effects

• CytotoxicityCell ViabilityUnknown

Drug Interactions

• Methylglyoxal-metabolizing agentsLow

Population Constraints

• General human populationRegulatory/safetyAbsolute

Regulatory Status

• European UnionUnapprovedResearch reagent; no marketing authorization.
• United StatesUnapprovedResearch chemical only; not an IND or approved drug.
• United KingdomUnapprovedResearch use only; no MHRA authorization.

Not approved by any regulatory authority for human therapeutic use. Used exclusively as a research/laboratory reagent and pharmacological tool.

Evidence & Sources

• Reaction mechanism of glyoxalase I explored by an X-ray crystallographic analysis of the human enzyme in complex with a transition state analogue
  Journal ArticleLowCameron AD, et al.1999-01-01T00:00:00.000000Z
• Residue R216 and catalytic efficiency of a murine class alpha glutathione S-transferase toward benzo[a]pyrene 7(R),8(S)-diol 9(S), 10(R)-epoxide
  Journal ArticleLowGu Y, Singh SV, Ji X2000-01-01T00:00:00.000000Z
• Glutathione S-transferases catalyzed conjugation of 1,4-disubstituted butanes with glutathione in vitro
  Journal ArticleLowMarchand DH, Abdel-Monem MM1985-01-01T00:00:00.000000Z
• Rose bengal-sensitized photooxidation of rat kidney gamma-glutamyltransferase
  Journal ArticleLowItoh K, Inoue M, Morino Y1984-01-01T00:00:00.000000Z
• Stereochemical aspects of conjugation reactions catalyzed by rat liver glutathione S-transferase isozymes
  Journal ArticleLowMangold JB, Abdel-Monem MM1983-01-01T00:00:00.000000Z
• Glutathione transport across hepatocyte plasma membranes. Analysis using isolated rat-liver sinusoidal-membrane vesicles
  Journal ArticleLowInoue M, et al.1984-01-01T00:00:00.000000Z

Frequently Asked Questions